Host Biomarkers Reflect Prognosis in Patients Presenting With Moderate Coronavirus Disease 2019: A Prospective Cohort Study
Chandna A., Mahajan R., Gautam P., Mwandigha L., Abhilash KPP., Balamugesh T., Burza S., Bhattacharjee A., Bhusan D., Chandna A., Cheung ATL., David T., Day N., Dayanand D., Dittrich S., Dondorp A., Gautam P., Geevar T., George B., Ghattamaneni SR., Gunasekaran K., Gupta R., Hansdak SG., Hussain S., Iyadurai R., Jimenez C., Karthik R., Karthikeyan R., Kazmi S., Koshiaris C., Kumar P., Kumar S., Kumar S., Kumar V., Kundu D., Lakshmanan A., Lubell Y., Mahajan R., Manesh A., Menggred C., Moorthy M., Mwandigha L., Osborn J., Richard-Greenblatt M., Sathyendra S., Sebastian M., Sharma S., Singh VK., Singh VK., Smith C., Suri J., Suzuki S., Tubprasert J., Turner P., Varghese G., Villanueva AMG., Waithira N., Zachariah A., Kumar P., Varghese GM., Koshiaris C., Lubell Y., Burza S.
Abstract Efficient resource allocation is essential for effective pandemic response. We measured host biomarkers in 420 patients presenting with moderate coronavirus disease 2019 and found that different biomarkers predict distinct clinical outcomes. Interleukin (IL)–1ra, IL-6, IL-10, and IL-8 exhibit dose-response relationships with subsequent disease progression and could potentially be useful for multiple use-cases.